We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Oxford Biomedica Plc | LSE:OXB | London | Ordinary Share | GB00BDFBVT43 | ORD 50P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 3.50 | 1.63% | 218.50 | 217.50 | 219.00 | 225.00 | 216.50 | 218.00 | 275,918 | 16:35:12 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Medicinal Chems,botanicl Pds | 139.99M | -45.16M | -0.4676 | -4.66 | 210.55M |
From Apr 2019 to Apr 2024
By Philip Waller
LONDON--Gene and cell therapy company Oxford BioMedica Plc (OXB.LN) Thursday reported a regulatory boost linked to a product that it supplies to Swiss drug company Novartis.
Oxford highlighted that Novartis had secured a fast-track review in the U.S. for a treatment for leukemia in children and young adults.
The U.S. Food & Drug Administration, or FDA, has granted priority review for Novartis's CTL019 investigational chimeric antigen receptor T-cell therapy, in relapsed and refractory pediatric and young adult patients with B-cell acute lymphoblastic leukemia.
The designation is expected to shorten the anticipated review time by the FDA.
Oxford BioMedica is the only maker of the lentiviral vector expressing CTL019 for Novartis.
Oxford's Chief Executive John Dawson said: "We continue to work closely with Novartis in delivering the lentiviral vector expressing CTL019, a product described earlier this year by Novartis as having 'blockbuster' potential."
Shares in Oxford BioMedica were up 0.16 pence, or 3.2%, at 5.2 pence.
Write to Philip Waller at philip.waller@wsj.com
(END) Dow Jones Newswires
March 30, 2017 05:06 ET (09:06 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
1 Year Oxford Biomedica Chart |
1 Month Oxford Biomedica Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
